Are non-small cell lung cancer patients with EML4-ALK fusion gene insensitive to cytotoxic chemotherapy?
NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy.
Despite increased LOS and hospital cost, a mortality benefit exists at HV centers. Future studies are necessary to determine other processes of care that may exist at HV centers that may account for this survival benefit.